查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2015466

弓浆虫病检测市场：市场洞察、竞争格局及市场预测（2033 年）

Toxoplasmosis Testing Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 188 Pages | 商品交期: 2-5个工作天内

价格
简介目录

随着全球医疗卫生系统日益重视早期诊断和感染疾病控制，全球弓形虫病检测市场正经历显着成长。弓形虫病是由弓形虫（Toxoplasma gondii）寄生虫引起的感染疾病，仍然是一个重要的公共卫生问题，尤其对孕妇和免疫力人群构成威胁。对快速准确检测日益增长的需求正在推动先进诊断解决方案的普及。预计到2026年，该市场规模将达24亿美元，2033年将成长至35亿美元，预测期内复合年增长率（CAGR）为5.50%。

市场洞察

随着包括血清学检测、分子诊断和影像技术在内的多种诊断技术的出现，弓形虫病检测市场正在不断发展。血清学检测因其价格低廉和易于获取而仍占据主导地位，但聚合酵素链锁反应(PCR) 等分子诊断技术因其准确性和可靠性而日益受到青睐。

通用感染疾病负担日益加重以及常规筛检计画（尤其是在产前保健领域）的扩展，正在推动市场成长。此外，检查室自动化和数位化诊断平台的进步提高了检测效率，缩短了结果报告时间，并增强了诊断的有效性和扩充性。

市场驱动因素

市场成长的主要驱动因素之一是全球弓形虫病感染率的上升。这种感染疾病可透过受污染的食物和水传播，也可透过接触受感染的动物传播，对已开发国家和开发中国家都构成广泛的风险。

另一个主要成长要素是人们对早期检测重要性的认识不断提高。早期诊断对于预防严重併发症至关重要，尤其是可能造成长期健康后果的性行为感染。

诊断工具的技术进步正在进一步加速市场扩张。高灵敏度和高特异性检测方法的开发，以及检查室自动化程度的提高，正在提升诊断的准确性和可近性。

此外，老年人和免疫力缺乏人群数量的增加也推动了对可靠检测解决方案的需求。这些弱势群体需要定期监测，这进一步促进了市场成长。

商业机会

弓形虫病检测市场为参与企业提供了巨大的成长机会。由于医疗基础设施的改善和医疗服务投资的增加，亚太地区和拉丁美洲等新兴经济体预计将成为主要的成长区域。

市场对能够快速提供准确结果的即时检测解决方案的需求日益增长。这些技术在偏远或资源匮乏的环境中特别有用，因为在这些地区，获得中心检查室检测服务可能受到限制。

此外，将人工智慧和数据分析等先进技术整合到诊断平台中，为创新开闢了新的途径。这些工具能够提高诊断准确性，提高工作流程效率，并为临床决策提供支援。

策略联盟、新产品发布和收购也为市场参与企业创造了巩固市场地位和拓展产品线的机会。持续加大研发投入可望推动市场创新与竞争力提升。

区域分析

北美在弓形虫病检测市场继续保持主导地位，这得益于其先进的医疗保健体系、高度的公众意识以及对创新诊断技术的积极应用。主要行业参与者的存在进一步巩固了该地区的市场主导地位。

欧洲占了较大的市场份额，这主要得益于政府主导的各项措施不断增加，以及对孕产妇和新生儿健康的高度重视。该地区完善的医疗卫生基础设施也为诊断检测的广泛普及提供了保障。

预计亚太地区在预测期内将经历最快的成长。快速的都市化、不断上涨的医疗保健成本以及人们对感染疾病认识的提高是该地区市场扩张的主要驱动因素。

拉丁美洲、中东和非洲也经历了温和增长，这得益于医疗保健服务的持续改善以及对疾病预防和早期诊断的日益重视。

主要企业

全球弓形虫病检测市场的特点是多家主要企业进入该市场，这些企业专注于创新和策略扩张。主要企业包括：

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Affymetrix Inc.
  • Beckman Coulter Inc.
  • Biotest
  • Cepheid Inc.
  • GenBio
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Biomerica Inc.
  • Biomerix

这些组织正积极致力于开发先进的诊断解决方案，并透过伙伴关係和产品创新在全球企业发展。

分割

按测试类型：

  • 血清学检测
  • 染色方法
  • 间接血凝反应
  • 直接团聚法
  • ELISA
  • PCR
  • 超音波检查
  • MRI
  • 切片检查

检体：

  • 血液检体
  • 羊水
  • 脑脊髓液

按最终用户划分：

  • 医院
  • 诊所
  • 诊断检查室

按地区划分：

  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东和非洲

目录

第一章执行摘要

第二章 市场概览

  • 市场定义与细分
  • 市场动态
    • 促进因素
    • 抑制因子
    • 市场机会
  • 价值链分析
  • 新冠疫情影响分析
  • 波特五力分析
  • 俄乌衝突的影响
  • PESTLE分析
  • 监管分析
  • 价格趋势分析
    • 当前价格及未来预测（2025-2033）
    • 价格影响因素

第三章：2020-2033年全球弓浆虫病检测市场展望

  • 全球弓浆虫病检测市场展望，按检测类型和价值（十亿美元）划分，2020-2033年
    • 血清学检测
    • 染料测试
    • 间接血凝试验
    • 直接凝集反应试验
    • ELISA
    • PCR
    • 超音波
    • MRI
    • 切片检查
  • 全球弓浆虫病检测市场展望，按检体类型和价值（十亿美元）划分，2020-2033年
    • 血液样本
    • 羊水
    • 脑脊髓液
  • 全球弓浆虫病检测市场展望（按最终用户划分，价值单位：十亿美元），2020-2033年
    • 医院
    • 诊所
    • 诊断检查室
  • 全球弓浆虫病检测市场展望（按地区划分，价值单位：十亿美元），2020-2033年
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第四章：2020-2033年北美弓浆虫病检测市场展望

第五章：2020-2033年欧洲弓浆虫病检测市场展望

第六章：2020-2033年亚太地区弓浆虫病检测市场展望

第七章：2020-2033年拉丁美洲弓浆虫病检测市场展望

第八章：2020-2033年中东和非洲弓形虫病检测市场展望

第九章 竞争情势

  • 公司与细分市场热图
  • 2025年各公司市占率分析
  • 竞争对手仪錶板
  • 公司简介
    • Abbott Laboratories
    • Bio-Rad Laboratories Inc.
    • Affymetrix Inc.
    • Beckman Coulter Inc.
    • Biotest
    • Cepheid Inc.
    • GenBio
    • Danaher Corporation
    • Thermo Fisher Scientific

第十章附录

简介目录

The global toxoplasmosis testing market is gaining notable momentum as healthcare systems worldwide intensify their focus on early diagnosis and infectious disease management. Toxoplasmosis, an infection caused by the parasite Toxoplasma gondii, remains a significant public health concern, particularly among pregnant women and individuals with weakened immune systems. The need for timely and accurate detection is driving the adoption of advanced diagnostic solutions. The market is projected to reach USD 2.4 billion in 2026 and is anticipated to grow to USD 3.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.50% during the forecast period.

Market Insights

The toxoplasmosis testing market is evolving with a wide array of diagnostic technologies, including serological assays, molecular diagnostics, and imaging techniques. Serological testing continues to dominate due to its affordability and accessibility, while molecular methods such as polymerase chain reaction (PCR) are increasingly preferred for their precision and reliability.

The growing burden of zoonotic diseases and the expansion of routine screening programs, particularly in prenatal care, are contributing to market growth. Additionally, advancements in laboratory automation and digital diagnostic platforms are enhancing testing efficiency and reducing turnaround times, making diagnostics more effective and scalable.

Market Drivers

A key factor driving market growth is the rising global incidence of toxoplasmosis infections. The infection can spread through contaminated food, water, and exposure to infected animals, making it a widespread risk across both developed and developing regions.

Increasing awareness regarding the importance of early detection is another major growth driver. Early diagnosis is essential in preventing severe complications, especially congenital infections that can have long-term health implications.

Technological progress in diagnostic tools is further accelerating market expansion. The development of highly sensitive and specific testing methods, along with automation in laboratories, is improving diagnostic accuracy and accessibility.

In addition, the growing population of elderly individuals and immunocompromised patients is increasing the demand for reliable testing solutions. These vulnerable groups require regular monitoring, further supporting the growth of the market.

Business Opportunity

The toxoplasmosis testing market offers substantial opportunities for industry participants. Emerging economies in Asia Pacific and Latin America are expected to be key growth areas due to improving healthcare infrastructure and rising investments in healthcare services.

There is a growing demand for point-of-care testing solutions that deliver rapid and accurate results. These technologies are particularly valuable in remote and resource-limited settings, where access to centralized laboratories may be limited.

Moreover, the integration of advanced technologies such as artificial intelligence and data analytics into diagnostic platforms is opening new avenues for innovation. These tools can enhance diagnostic accuracy, streamline workflows, and support clinical decision-making.

Strategic collaborations, product launches, and acquisitions are also creating opportunities for market players to strengthen their presence and expand their product offerings. Continuous investment in research and development is expected to drive innovation and competitiveness in the market.

Region Analysis

North America continues to hold a leading position in the toxoplasmosis testing market, supported by advanced healthcare systems, high awareness levels, and strong adoption of innovative diagnostic technologies. The presence of major industry players further reinforces the region's dominance.

Europe represents a significant share of the market, driven by increasing government initiatives and a strong emphasis on maternal and neonatal health. The region's well-established healthcare infrastructure supports widespread adoption of diagnostic testing.

Asia Pacific is projected to witness the fastest growth over the forecast period. Rapid urbanization, rising healthcare expenditure, and increasing awareness about infectious diseases are key factors contributing to market expansion in the region.

Latin America and the Middle East & Africa are also experiencing gradual growth, supported by ongoing improvements in healthcare access and increasing focus on disease prevention and early diagnosis.

Key Players

The global toxoplasmosis testing market is characterized by the presence of several prominent players focused on innovation and strategic expansion. Key companies include:

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Affymetrix Inc.
  • Beckman Coulter Inc.
  • Biotest
  • Cepheid Inc.
  • GenBio
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Biomerica Inc.
  • Biomerix

These organizations are actively engaged in developing advanced diagnostic solutions and expanding their global footprint through partnerships and product innovations.

Segmentation

By Test Type:

  • Serological Test
  • Dye Test
  • Indirect Hemagglutination Assay
  • Direct agglutination Assay
  • ELISA
  • PCR
  • Ultrasound
  • MRI
  • Biopsy

By Sample:

  • Blood Sample
  • Amniotic Fluid
  • Cerebrospinal Fluid

By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Toxoplasmosis Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Toxoplasmosis Testing Market Outlook, 2020-2033

  • 3.1. Global Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Serological Test
    • 3.1.2. Dye Test
    • 3.1.3. Indirect Hemagglutination Assay
    • 3.1.4. Direct agglutination Assay
    • 3.1.5. ELISA
    • 3.1.6. PCR
    • 3.1.7. Ultrasound
    • 3.1.8. MRI
    • 3.1.9. Biopsy
  • 3.2. Global Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 3.2.1. Blood Sample
    • 3.2.2. ABniotic Fluid
    • 3.2.3. Cerebrospinal Fluid
  • 3.3. Global Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospitals
    • 3.3.2. Clinics
    • 3.3.3. Diagnostic Laboratories
  • 3.4. Global Toxoplasmosis Testing Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Toxoplasmosis Testing Market Outlook, 2020-2033

  • 4.1. North America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Serological Test
    • 4.1.2. Dye Test
    • 4.1.3. Indirect Hemagglutination Assay
    • 4.1.4. Direct agglutination Assay
    • 4.1.5. ELISA
    • 4.1.6. PCR
    • 4.1.7. Ultrasound
    • 4.1.8. MRI
    • 4.1.9. Biopsy
  • 4.2. North America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 4.2.1. Blood Sample
    • 4.2.2. ABniotic Fluid
    • 4.2.3. Cerebrospinal Fluid
  • 4.3. North America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Diagnostic Laboratories
  • 4.4. North America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.2. U.S. Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 4.4.3. U.S. Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.5. Canada Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 4.4.6. Canada Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Toxoplasmosis Testing Market Outlook, 2020-2033

  • 5.1. Europe Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Serological Test
    • 5.1.2. Dye Test
    • 5.1.3. Indirect Hemagglutination Assay
    • 5.1.4. Direct agglutination Assay
    • 5.1.5. ELISA
    • 5.1.6. PCR
    • 5.1.7. Ultrasound
    • 5.1.8. MRI
    • 5.1.9. Biopsy
  • 5.2. Europe Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 5.2.1. Blood Sample
    • 5.2.2. ABniotic Fluid
    • 5.2.3. Cerebrospinal Fluid
  • 5.3. Europe Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Diagnostic Laboratories
  • 5.4. Europe Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.2. Germany Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.3. Germany Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.5. Italy Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.6. Italy Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.7. France Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.8. France Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.9. France Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.11. U.K. Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.12. U.K. Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.14. Spain Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.15. Spain Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.17. Russia Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.18. Russia Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.20. Rest of Europe Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.21. Rest of Europe Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Toxoplasmosis Testing Market Outlook, 2020-2033

  • 6.1. Asia Pacific Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Serological Test
    • 6.1.2. Dye Test
    • 6.1.3. Indirect Hemagglutination Assay
    • 6.1.4. Direct agglutination Assay
    • 6.1.5. ELISA
    • 6.1.6. PCR
    • 6.1.7. Ultrasound
    • 6.1.8. MRI
    • 6.1.9. Biopsy
  • 6.2. Asia Pacific Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 6.2.1. Blood Sample
    • 6.2.2. ABniotic Fluid
    • 6.2.3. Cerebrospinal Fluid
  • 6.3. Asia Pacific Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Diagnostic Laboratories
  • 6.4. Asia Pacific Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.2. China Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.3. China Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.5. Japan Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.6. Japan Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.8. South Korea Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.9. South Korea Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.10. India Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.11. India Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.12. India Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.14. Southeast Asia Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.15. Southeast Asia Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.17. Rest of SAO Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.18. Rest of SAO Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Toxoplasmosis Testing Market Outlook, 2020-2033

  • 7.1. Latin America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Serological Test
    • 7.1.2. Dye Test
    • 7.1.3. Indirect Hemagglutination Assay
    • 7.1.4. Direct agglutination Assay
    • 7.1.5. ELISA
    • 7.1.6. PCR
    • 7.1.7. Ultrasound
    • 7.1.8. MRI
    • 7.1.9. Biopsy
  • 7.2. Latin America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 7.2.1. Blood Sample
    • 7.2.2. ABniotic Fluid
    • 7.2.3. Cerebrospinal Fluid
  • 7.3. Latin America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Diagnostic Laboratories
  • 7.4. Latin America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.2. Brazil Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.3. Brazil Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.5. Mexico Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.6. Mexico Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.8. Argentina Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.9. Argentina Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.11. Rest of LATAM Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.12. Rest of LATAM Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Toxoplasmosis Testing Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Serological Test
    • 8.1.2. Dye Test
    • 8.1.3. Indirect Hemagglutination Assay
    • 8.1.4. Direct agglutination Assay
    • 8.1.5. ELISA
    • 8.1.6. PCR
    • 8.1.7. Ultrasound
    • 8.1.8. MRI
    • 8.1.9. Biopsy
  • 8.2. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 8.2.1. Blood Sample
    • 8.2.2. ABniotic Fluid
    • 8.2.3. Cerebrospinal Fluid
  • 8.3. Middle East & Africa Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Diagnostic Laboratories
  • 8.4. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.2. GCC Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.3. GCC Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.5. South Africa Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.6. South Africa Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.8. Egypt Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.9. Egypt Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.11. Nigeria Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.12. Nigeria Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.14. Rest of Middle East Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.15. Rest of Middle East Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Abbott Laboratories
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Bio-Rad Laboratories Inc.
    • 9.4.3. Affymetrix Inc.
    • 9.4.4. Beckman Coulter Inc.
    • 9.4.5. Biotest
    • 9.4.6. Cepheid Inc.
    • 9.4.7. GenBio
    • 9.4.8. Danaher Corporation
    • 9.4.9. Thermo Fisher Scientific

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations